El Demery Mounira, Demirdjian-Sarkissian Gaiané, Thezenas Simon, Jacot William, Laghzali Yassine, Darbouret Bruno, Culine Stéphane, Rebillard Xavier, Lamy Pierre-Jean
Department of Medical Oncology, Cap d¿Or Clinic, La Seyne sur Mer, France.
Clinical Diagnostic Division, Thermo Fisher Scientific, Nimes, France.
Clin Transl Med. 2014 Oct 28;3:31. doi: 10.1186/s40169-014-0031-4. eCollection 2014.
Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer.
Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology.
The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ?11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R?=?2.1, 95% CI, 1.1 to 4.4).
Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.
尿液标志物已得到广泛研究，但膀胱癌缺乏血液预后标志物。基质金属蛋白酶-7（MMP-7）由基质细胞和肿瘤细胞产生，在多种上皮和间充质肿瘤中过表达。在本研究中，我们使用自行开发的免疫测定法评估了血清MMP-7在一系列晚期膀胱癌患者中的预后价值。
收集了2003年3月至2004年12月在蒙彼利埃癌症研究所接受治疗的56例晚期膀胱癌患者的血清样本。通过使用我们基于时间分辨放大镧系荧光发光（TRACE）技术开发的均相夹心荧光免疫测定法对血清样本中的MMP-7进行定量。
研究人群的中位总生存期为2.2年（95%CI，1.4至3.0），1年和5年生存率分别为73%（95%CI，59%至82%）和25%（95%CI，14%至37%）。高血清MMP-7水平与生存不良相关。使用11.5 ng/mL的临界值，MMP-7血清水平<11.5 ng/mL的患者中位总生存期为3.0年（95%CI，1.5至5.1），血清水平≥11.5 ng/mL的患者为1.3年（95%CI，0.8至2.5）。多变量分析确定高血清MMP-7浓度是晚期膀胱癌患者生存的独立预后因素（R=2.1，95%CI，1.1至4.4）。
我们的结果表明，血清MMP-7浓度是局部晚期和/或转移性膀胱癌患者的独立预后因素。
